Deputy Director, Office of Biostatistics, Office of Translational Sciences, CDER, FDA
Dr. Chakravarty joined CDER in 1992. She is an internationally recognized thought leader in the area of safety evaluation, surrogate markers and biomarkers in drug development and has presented and published widely on it. Dr. Chakravarty received the FDA Award of Merit in 2008 and...
Read More →
Head, Regional Regulatory (Innovative) Asia Pacific, Pfizer Inc
Dr. Rominder (Romi) Singh has extensive scientific and management experience at top biopharmaceutical companies--Pfizer, Amgen, Merck and GlaxoWellcome. His experience spans across drug development—drug discovery to commercialization. He is recognized as an expert on international...
Read More →
Principal reviewer, Office of New Drug V, Pharmaceuticals and Medical Devices Agency (PMDA)
Dr. Yoko Aoi is a principal reviewer of Office of New Drug V responsible for review and scientific advice on oncology drugs. After joining PMDA, Dr. Aoi was involved in review and scientific advice on new drugs for rheumatoid arthritis, asthma, COPD etc. (2011-2016) and planning and...
Read More →
Vice President, Clinical Development, Merck & Co., Inc.
Stuart Green trained in Internal Medicine, Pulmonary Medicine and Critical Care Medicine at Duke University Medical Center, Durham, NC USA. In addition to clinical work, his major research efforts focused on the structure and function of airway G-protein coupled receptors, primarily...
Read More →